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Monoclonal regulatory T cells 
provide insights into T cell 
suppression
Céline Gubser1, Mathias Schmaler2, Simona W. Rossi3 & Ed Palmer1
Regulatory T cells (Tregs) have a crucial role in maintaining lymphocyte homeostasis. However an 
understanding of how Tregs function at a cellular and molecular level has not yet been fully elucidated. 
Here, we make use of a T cell receptor (TCR) transgenic, Rag−/− mouse expressing a Forkhead-Box-
Protein P3 (Foxp3) transgene. This mouse provides a source of monoclonal CD4+ Foxp3+ T cells with a 
defined specificity. Here we show that monoclonal B3K506 Tregs are functional in vitro and in vivo and 
clearly require cognate antigen to be suppressive. We further show that the strength of Treg stimulation 
determines the strength of Treg mediated suppression. Finally we analysed various suppressive 
mechanisms used by monoclonal Tregs and found that Treg-Tconv proximity is a parameter, which 
correlates with enhanced suppression.
CD4+ CD25+ Foxp3+ regulatory T cells (Tregs) are critically involved in the maintenance of lymphocyte homeo-
stasis1. Absence of functional Tregs leads to massive cytokine secretion and multi-organ lymphocytic infiltration 
resulting in polyendocrinopathies and enteropathies (i.e. colitis), a condition termed “scurfy” in the mouse2 and 
immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) in the human3.
The Treg TCR repertoire has been described as enriched in self-reactive TCRs, specific for tissue-restricted 
antigens presented in the periphery4–6. Encounter of peripheral self-antigens allows constant activation and sur-
vival of Tregs7,8. Despite the self-reactivity of Tregs, the role of TCR signalling in Treg biology has been controver-
sial and is still not fully understood. Numerous reports support the idea that TCR signalling in Tregs is uncoupled 
from the signalling pathways described in conventional T cells9,10. The idea that TCR stimulation is blunted or 
deviated to maintain an anergic, suppressive Treg phenotype has received experimental support. These results 
raised questions whether TCR signalling is even required for Treg mediated suppression11. However recent data, 
using a model where the TCR can be deleted in peripheral Tregs, show that continuous expression and signalling 
through the TCR is required for effective suppression to occur in vivo12. Loss of TCR in peripheral Tregs resulted 
in lethal autoimmunity12.
Previous work characterized Tregs and described their suppressive mechanisms. These mechanisms can be 
divided into two main groups, i.e. those that depend on cell-cell contact and those that do not. Studies using 
transwell suppression assays, suggested a predominant role for cell-cell contact dependent suppressive mecha-
nisms13,14. However, a failure to observe suppression in these experiments could be explained by the inability of 
diffusible Treg-derived suppressive molecules to function in the relatively large volume of the in vitro culture. 
Theoretically, suppression might depend on Treg-secreted molecules but additionally require proximity between 
Tregs and Tconv cells15. Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) is constitutively expressed on 
Tregs16 and thought to be important for suppression. Mice with Treg specific CTLA-4 deficiency suffer from 
spontaneous development of systemic lymphoproliferation and fatal T cell autoimmunity17. It has been suggested 
that Tregs initiate the catabolism of tryptophan in dendritic cells through a CD80/86-CTLA-4 dependent mech-
anism, generating metabolites, which convert naïve CD4 Tconvs into induced Tregs (iTregs) with tolerogenic 
properties18–20. It was shown that CTLA-4 down regulates co-stimulatory molecules CD80 and CD86 on antigen 
presenting cells (APCs) via trans-endocytosis21–23. By diminishing the APC’s capacity to costimulate T cells, Tregs 
may prevent priming of Tconvs24,25. Another suppressive mechanism involves high expression of lymphocyte 
1Departments of Biomedicine and Nephrology, University Hospital Basel and University of Basel, 4031 Basel, 
Switzerland. 2Laboratory of Experimental Immunology, Department of Biomedicine, University Hospital Basel and 
University of Basel, 4031 Basel, Switzerland. 3Laboratory of Regulatory Immunology Department of Biomedicine, 
University Hospital Basel and University of Basel, 4031 Basel, Switzerland. Correspondence and requests for 
materials should be addressed to E.P. (email: ed.palmer@unibas.ch)
Received: 22 October 2015
accepted: 22 April 2016
Published: 23 May 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:25758 | DOI: 10.1038/srep25758
function-associated antigen 1 (LFA-1) on Tregs, which has been proposed to augment the physical interaction 
between Tregs and APCs. In this way, Tregs may out compete Tconvs for “space” on the APC26.
Considering mechanisms that are cell-contact independent, Tregs secrete TGFβ and IL-10 immunosup-
pressive cytokines, which have been shown to control Tconv proliferation27,28. Treg derived TGFβ was shown 
to convert naïve T cell precursors into iTregs29. However, the role of TGFβ in Treg suppression remains contro-
versial since Tregs mediate suppression of Tconvs from TGFβ RII−/− and Smad3−/− mice30. In addition, Tregs 
from neonatal TGFβ −/− mice retained their suppressive capacity30. Gut Tregs were shown to secrete IL-10, which 
was required for mucosal immune homeostasis and control of colitis31–33. However, Treg specific IL-10 deficient 
mice do not suffer from systemic autoimmunity per se; rather they fail to control immune responses at mucosal/
environmental interfaces (i.e. gut, lung)34. Furthermore, blocking either IL-10 or TGFβ failed to abrogate Treg 
mediated suppression in vitro35.
Tregs have additionally been shown to disrupt Tconv metabolism through cyclic adenosine monophosphate 
(cAMP)36,37 or by scavenging cytokines38. In this regard, Tregs constitutively express high levels of the IL-2 recep-
tor alpha chain (CD25), which might be able to scavenge IL-2 from Tconvs, preventing their full activation39. 
On the other hand, two observations question the idea that Tregs function by consuming (i.e. scavenging) 
Tconv-generated IL-2: (i) Tregs from CD25−/− mice are suppressive in vitro39 and (ii) mice with a deletion of 
the IL-2Rβ (CD122) gene limited to peripheral Tregs don’t suffer from autoimmune disorders40. However more 
recent work mitigated these interpretations. CD122 deficient Tregs still respond to IL-2, albeit to a diminished 
extent41. CD25 deficient Tconvs exhibit a compensatory up-regulation of CD122 and the common gamma chain 
(CD132)42, which renders them capable of responding to, and consuming IL-2. This may occur on CD25 deficient 
Tregs as well15. Finally, another line of evidence for IL-2 consumption as a suppressive mechanism lies in the fact 
that addition of exogenous IL-2 abrogates suppression (in vitro)13,14.
Here, we attempt to re-assess some of the mechanisms of Treg mediated suppression and the TCR’s contribu-
tion. To investigate the mechanism of suppression it would be valuable to have a source of monoclonal Tregs. A 
difficulty of most monoclonal TCR Tg mice is, they contain very few Tregs. To circumvent this problem we bred 
Foxp3 transgenic mice43 to animals carrying the MHC II restricted B3K506 TCR transgene44. Using these B3K506 
TCR Tg Rag−/− Foxp3 Tg mice as a source of monoclonal Tregs (B3K506 Tregs), we analysed several parameters 
for their influence on Treg mediated suppression. The results indicate that the strength of Treg stimulation by 
peptide-MHC (pMHC) antigen determines the strength of Treg mediated suppression. Furthermore the data 
show that Treg-Tconv proximity could be an important component of suppression.
Results
Generating mice producing monoclonal Tregs. A Foxp3 transgene43 was backcrossed to TCR trans-
genic B3K506 Rag−/− mice44 to generate Rag−/−, B3K506 TCR transgenic, Foxp3 transgenic (B3K506 Treg) mice. 
Forty-50% of T cells in this strain were Foxp3+ (Fig. 1a). This contrasts with T cells from Rag−/−, B3K506 TCR 
transgenic (B3K506 Tconv) mice, where > 99% T cells were Foxp3-negative (Tconvs) (Fig. 1a). Compared to poly-
clonal B6 Tregs, monoclonal B3K506 Tregs expressed slightly reduced levels of CD25, glucocorticoid-induced 
TNFR-related protein (GITR) and LFA-1, and clearly decreased amounts of CTLA-4 (Fig. 1b). B3K506 Tregs 
neither expressed Helios nor neuropilin 1 (NRP-1) (Fig. 1b).
B3K506 Treg mice were lymphopenic and were therefore treated with IL-2 bound to JES6-1 monoclonal anti-
bodies for specific enrichment of Tregs (see Supplementary Fig. S1). The capacity of monoclonal B3K506 Tregs 
to suppress polyclonal CD4+ conventional T cells (Tconvs) was assessed in vitro using anti-CD3 as a stimulus 
(Fig. 1c). No significant difference between the suppressive capacity of monoclonal B3K506 and polyclonal B6 
Tregs was observed. As expected, B3K506 Tconv cells were not suppressive (Fig. 1c,d). We also established a 
peptide specific suppression assay using monoclonal B3K506 Tregs and monoclonal CD4+ OT-II Tconvs (the 3K 
peptide is specific for B3K506 Tregs and OVA323-339 peptide is specific for OT-II Tconvs: Fig. 1e,f). B3K506 Tregs 
clearly required TCR stimulation to induce suppressive activity, while antigen stimulated B3K506 Tconvs do not 
induce suppression (Fig. 1e,f).
B3K506 monoclonal Tregs require antigen recognition to mediate suppression. We wondered 
whether antigen stimulated Tregs influence the survival/expansion and functional profile of co-cultured OT-II 
Tconvs. Therefore, we analysed live cell numbers of B3K506 Tregs and OT-II Tconvs as well as cytokine concen-
trations in supernatants of suppressive (+ 3K peptide) and non-suppressive (− 3K peptide) cultures (Fig. 2a–c). In 
suppressive cultures, OT-II Tconvs proliferate poorly (Fig. 2a, top) and secrete reduced amounts of IFNγ and IL-2 
(Fig. 2b,c). This is consistent with the observation that suppressed OT-II Tconvs are less activated and express less 
CD25 and CD69 than non-suppressed OT-II Tconvs (see Supplementary Fig. S1). Furthermore, B3K506 Tregs 
accumulated in antigen-stimulated cultures but not in cultures lacking 3K peptide (Fig. 2a).
B3K506 Tregs also required antigen stimulation for suppressive activity in vivo. We made use of a previously 
established tolerance model45 where skin grafts from B6 I-Abm12 Rag−/− donor mice were transplanted onto B6 
I-Ab Rag−/− mice and 14d later challenged with a combination of adoptively transferred ABM (I-Abm12 specific) 
TCR Tg Tconvs and B3K506 Tregs in the presence or absence of the cognate 3K peptide (Fig. 2d,e). Administering 
3K peptide until day 15 induced graft survival lasting ≥ 75 days in 50% of the transplanted mice. All transplanted 
animals, which didn’t receive 3K peptide rejected their grafts by day 17. A few animals from both groups (receiv-
ing or not receiving 3K peptide) where sacrificed and analysed on day 21 post adoptive T cell transfer. Mice 
tolerating their graft (Fig. 2f, top row) contained many B3K506 Tregs and only few ABM Tconvs in the draining 
LN. Mice, which rejected their graft in spite of receiving 3K peptide contained many ABM Tconvs but fewer 
Foxp3+ B3K506 Tregs (Fig. 2f, bottom row). Finally mice, which did not receive 3K peptide rejected their grafts 
and contained almost no B3K506 Tregs (Fig. 2g). These results show that antigen recognition by the Treg is clearly 
required for suppression, both in vitro and in vivo.
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Suppression correlates with strength of antigen stimulation, Treg numbers, and CD25 expression. 
To further investigate the role of antigen recognition in suppression, B3K506 Tregs were stimulated with several 
altered peptide ligands. At various times, cultures were assessed for the frequency, absolute cell number (Fig. 3a), 
CD25 expression (Fig. 3b) and suppressive capacity (Fig. 3C) of CD4high, Foxp3high B3K506 Tregs. When used at 
a concentration of 10e-8M to 10e-5M, stimulation with the high affinity ligand 3K resulted in high numbers of 
surviving B3K506 Tregs and significant OT-II Tconv suppression (Fig. 3a,c). However, only high concentrations 
(10e-6 to 10e-5M) of the intermediate affinity ligand, P8G induced Treg survival and significant suppression 
Figure 1. (a) Representative flow cytometry plots of CD4+ LN T cells from B3K506TCR Tg Rag−/− (B3K506 
Tconv) and B3K506 TCR Tg Foxp3 Tg Rag−/− (B3K506 Treg) mice are shown. Numbers in plots depict % of 
cells in the quadrant. (b) Representative histograms show surface marker expression on monoclonal LN 
B3K506 Tregs ( ), polyclonal B6 Foxp3EGFP Tregs (----), polyclonal B6 Tconvs ( ) and monoclonal LN 
B3K506 Tconvs ( ), n = 4. (c) In vitro anti-CD3ε suppression assays. Representative proliferation of 
polyclonal B6 CD4+ Tconvs co-cultured with polyclonal B6 Foxp3EGFP Tregs ( ), monoclonal B3K506 Tregs ( ) 
or B3K506 Tconv ( ) at a 1Tconv/4Treg ratio. Grey histograms indicate proliferation of B6 CD4+ Tconvs cultured 
without Tregs. Numbers in histograms depict % proliferated cells. Graph shows mean % suppression + /− SD at 
72h, n = 5. (d) In vitro anti-CD3ε suppression assays. Capacity of monoclonal B3K506 Tregs ( ), polyclonal B6 
Foxp3EGFP Tregs ( ) and monoclonal B3K506 Tconv (negative control; ) to suppress proliferation of 
polyclonal B6 CD4+ T cells at varying Treg/Tconv ratios. Data show mean % suppression + /− SD, n = 3. (e/f) 
Antigen stimulated suppression assays. (e) CFSE labelled OT-II Tconvs were co-cultured with B3K506 Tregs at a 
1Tconv/4Treg ratio in the presence ( ) or absence ( ) of 3K peptide, or with B3K506 Tconv ( ) in the 
presence of 3K peptide. All cultures contained OVA peptide. OT-II Tconv proliferation in the absence of Tregs is 
shown ( ). Numbers in histograms represent % proliferated cells. (f) OT-II Tconv proliferation index and % 
suppression in co-cultures described in E). Monoclonal B3K506 Tregs + 3K peptide ( ); monoclonal B3K506 
Tregs −3K peptide ( ); monoclonal B3K506 Tconvs ( ); OT-II Tconvs alone ( ). All cultures contained OVA 
peptide. Data show mean proliferation index + /− SD, n = 9–12. Statistical significance was calculated using a 
one-way ANOVA and subsequently Bonferroni’s multiple comparisons test. NS = p > 0.05, *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001, ****p ≤ 0.0001.
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(Fig. 3a,c). B3K506 Treg survival and suppression were poorly induced by the threshold affinity ligand, P2A 
(Fig. 3a). However, some suppression of OT-II proliferation could still be observed in co-cultures stimulated with 
high (10e-5M) P2A concentrations in the cultures (Fig. 3c). All peptide ligands were similarly suppressive when 
applied at their EC50 concentration as measured by CD69 up regulation (see Supplementary Fig. S2).
The suppressive capacity of B3K506 Tregs clearly correlated with pMHC affinity and peptide concentration 
(Fig. 3d) as well as with TCR signal strength, a parameter, which combines pMHC affinity for the TCR and pep-
tide concentration (Fig. 3e). Suppression also correlated with the number of surviving B3K506 Tregs (Fig. 3f) and 
the amount of CD25 they express (Fig. 3g). High Treg cell numbers can compensate for low CD25 expression 
Figure 2. (a) Stimulated B3K506 Tregs outcompete OT-II Tconvs, in vitro. Representative flow cytometry plots 
show % of OT-II Tconvs and B3K506 Tregs cocultured at a 1Tconv/4Treg ratio in suppressive (with 3K peptide) and 
non-suppressive (without 3K peptide) co-cultures at 72h. Numbers in the plots represent % of live cells in gate. 
Graphs show mean numbers + /− SD of live OT-II Tconvs ( ) and B3K506 Tregs ( ) from co-cultures 
described in A), n = 3. (b) Left: Graph depicts mean IFNγ (pg/ml) + /− SD in supernatants of suppressive (red) 
and non-suppressive (black) co-cultures at a 1Tconv/4Treg ratio, n = 3. Right: Representative flow cytometry plots 
show intracellular IFNγ staining of OT-II Tconvs in suppressive ( ) vs. non-suppressive (-----) co-cultures. 
(c) Left: Graph depicts mean IL-2 (pg/ml) + /− SD in supernatants of suppressive ( ) and non-suppressive 
(-----) co-cultures at a 1Tconv/4Treg ratio, n = 3. Right: Representative flow cytometry plots show GFP expression 
from eFluor labelled OT-II IL-2GFP reporter Tconvs in suppressive ( ) vs. non-suppressive (-----) co-
cultures. (d) Experimental design of in vivo suppression assay. Dot plots show PBMCs from a B6 I-Ab Rag−/− 
host (recipient mouse) which had been grafted with skin from a B6 I-Abm12 Rag−/− donor mouse prior to T-cell 
transfer. (e) Skin from B6 I-Abm12 Rag−/− donor mouse was transplanted onto B6 I-Ab Rag−/− mice and allowed 
to heal for 14 days. The following day mice were injected with 2 × 10e4 ABM (I-Abm12 specific) Tconvs along 
with polyclonal B6 Foxp3EGFP Tregs ( ) or monoclonal B3K506 Tregs (  and  ). An additional 
group ( ) was injected with ABM Tconvs alone. One group ( ) received 3K peptide (30 μ g per mouse, 
i.p. every second day) until day 15. Graph shows % graft survival + /− SD vs. time. Each group contains 5 to 8 
mice and results are pooled from 2 independent experiments. (f) Representative flow cytometry plots show 
ABM Tconvs and B3K506 Tregs from the draining LN of skin-grafted mice. Cells in upper plots are from a 
mouse which received 3K peptide and accepted the skin graft, while cells in lower plots are from a mouse which 
rejected it’s graft, despite receiving the Treg cognate peptide, 3K. Number in the plots depict % of cells in each 
gate/quadrant. (g) Representative flow cytometry plot showing ABM Tconvs and B3K506 Tregs from the 
draining LN of skin-grafted mice, which did not receive 3K peptide treatment and rejected their graft. Numbers 
in the plot depict % of cells in each gate/quadrant.
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(e.g.10e-7M 3K, compare red triangles in 3f and 3g) and vice versa (e.g.10e-5M 3K, compare red circles in 3f and 
3g). Finally, there is a clear threshold below which, low Treg cell numbers and CD25 expression fail to induce 
suppression. These results strongly suggest that the strength of Treg stimulation by its cognate antigen drives 
suppression through induction of Treg expansion, survival and CD25 expression.
Suppression is enhanced by Treg and Tconv proximity. We also examined the roles of various sup-
pressive mechanisms using this experimental system. Culture supernatants from separately cultured antigen stim-
ulated B3K506 Tregs, did not suppress the antigen driven expansion of (separately cultured) antigen stimulated 
OT-IIs, which argues against the presence of soluble suppressive molecules produced at effective concentrations 
in this system (Fig. 4a). In suppressive (with 3K peptide) and non-suppressive (without 3K peptide) co-cultures, 
CD86 expression on splenic B cell APCs and surviving splenic B cell numbers were similar (Fig. 4b). This argues 
that a Treg mediated decrease of CD86 on surviving APCs (i.e. via trans endocytosis) or a Treg mediated killing of 
APCs was not obviously required for suppression in these cultures. Furthermore, B3K506 Tregs did not convert 
OT-II Tconvs into iTregs (Fig. 4c) even though B3K506 Tregs expressed high levels of surface latency-associated 
peptide of TGF-β (LAP) (see Supplementary Fig. S2)
Finally, we wondered whether Tregs and Tconv needed to encounter their cognate peptide on the same APC 
for effective suppression to occur. To avoid cross-presentation of the Treg and Tconv peptides, we used I-Ed 
restricted HA transgenic Tconvs, whose cognate peptide, HA cannot be presented by I-Ab. In this system, peptide 
cross presentation and alloreactions were not evident (see Supplementary Fig. S2). I-Ab restricted B3K506 Tregs 
Figure 3. (a) Representative flow cytometry plots show B3K506 Tregs from suppressive co-cultures stimulated 
with various B3K506 altered peptide ligands at a 1Tconv/4Treg ratio at 72h. Numbers in the plots depict % of 
cells in each quadrant. Bar graph shows mean number of B3K506 Tregs + /− SD from these cultures at 72 h, 
n = 5. (b) Representative histograms show CD25 expression (MFI) on CD4high Foxp3high B3K506 Tregs from 
suppressive co-cultures stimulated with various altered peptide ligands or no peptide at a 1Tconv/4Treg ratio at 
72 h. (c) Representative histograms depict proliferation of CFSE labelled OT-II Tconvs form suppressive co-
cultures described in A). Bar graph shows mean proliferation index + /− SD of OT-II Tconvs at 72 h, n = 4–8. 
(a–c) Statistical significance was calculated using a one-way ANOVA and subsequently a Bonferroni’s multiple 
comparisons test. NS = p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 (d) Curves show correlation 
between pMHC affinity (1/KD) for the B3K506 TCR and OT-II proliferation index from suppressive co-
cultures described in A). APCs were pulsed with 10e-8M peptides (◽ ) or 10e-5M peptides (⚬ ). (e) Curve shows 
correlation between OT-II Tconv proliferation index and B3K506 Treg stimulus strength, which combines 
pMHC affinity and peptide concentration and is defined as [1/KD x peptide conc. (μ M)] from suppressive co-
cultures described in A). Curve is a nonlinear fit with variable slope (4 parameters). (f) Correlation between 
OT-II Tconv proliferation index and number of surviving Tregs from suppressive co-cultures described in A). 
Curve is a nonlinear fit with variable slope (4 parameters). (g) Correlation between OT-II Tconv proliferation 
index and CD25 expression (MFI) on surviving Tregs from suppressive co-cultures described in A). Curve is a 
nonlinear fit with variable slope (4 parameters).
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and I-Ed restricted HA Tconvs were co-cultured with B6xBalb/c F1 splenic B cell APCs loaded with both the 3K 
and HA peptides. This arrangement was referred to as “same APC”. Alternatively, B3K506 Tregs and HA Tconvs 
were co-cultured with B6 splenic B cell APCs loaded with 3K only and Balb/c splenic B cells loaded with HA pep-
tide only. This arrangement was called “separate APCs”. Results show that suppression was enhanced when both 
antigens were presented on the same APC (Fig. 4d). However, antigens presented on separate APCs were able to 
support some degree of suppression, as up regulation of CD25 on HA Tconvs was suppressed in these separate 
APC co-cultures (Fig. 4e). Taken together, these data suggest that increased proximity between Tregs and Tconvs 
improves suppression.
Discussion
Here we show that monoclonal B3K506 Tregs are functional in vitro and in vivo; furthermore, Tregs clearly require 
cognate antigen stimulation to be suppressive. Our data also show that the strength of Treg TCR stimulation cor-
relates with the extent of Treg mediated suppression. Increasing the affinity and/or concentration of Treg antigen 
drives Treg proliferation and CD25 expression, which is likely related to the extent of suppression in this system.
Figure 4. (a) Supernatants from stimulated Treg cultures are not suppressive. Graph depicts mean proliferation 
index + /− SEM of OT-II Tconvs separately cultured in various concentrations of supernatant from separately 
stimulated B3K506 Treg cultures, n = 3. Representative histograms depict proliferation of OT-II Tconvs cultured 
in media containing 50% Treg supernatant ( ) or in media alone ( ). (b) Tregs do not affect CD86 
expression on APCs or APC cell numbers. Top: Bar graph depicts % of CD86+ splenic B cell APCs from 
suppressive (with 3K peptide, ) and non-suppressive (without 3K peptide, -----) co-cultures. 
Representative flow cytometry plots show CD86 expression on live, CD19+ CD4− splenic B cell APCs from 
these cultures at 72h. Numbers in the plots depict % of cells in each quadrant. Bottom: Graph shows mean 
number of live splenic B cell APCs + /− SD vs. time in suppressive vs. non-suppressive co-cultures at various 
times, n = 3. (c) B3K506 Tregs do not convert OT-II Tconvs into induced Tregs (iTregs). Representative flow 
cytometry plots show Foxp3 and CD4 expression on OT-II Tconvs from suppressive co-cultures at a 1Tconv/4Treg 
ratio at 72 h. Numbers in the plots depict % of cells in each quadrant or gate. (d) Suppression is enhanced when 
Treg and Tconv antigens are presented on the same APC. Left: Representative histograms show proliferation of 
CFSE labelled HA Tconvs co-cultured with B3K506 Tregs at a 1Tconv/4Treg ratio. HA Tconvs and B3K506 Tregs 
encounter their cognate ligand either on the same (top) or on separate (bottom) splenic B cell APCs (see 
diagram). Suppressive cultures ( ) were compared to non-suppressive cultures where 3K peptide was 
omitted (-----). Right: Graph shows mean % suppression (top) and mean proliferation index (bottom) + /− SD 
of HA-Tconvs co-cultured in the different conditions described in D, n = 4–5. (e) Left: Representative flow 
cytometry plots show CD25 expression on HA Tconvs in cultures described in D). Numbers in the plots 
represent % of cells in each quadrant. Right: Bar graph depicts mean % CD25+ HA-Tconvs + /− SD in these 
cultures at 72 h, n = 4.
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B3K506 Treg mice are lymphopenic and only 40–50% of CD4 T cells are Foxp3+ (Fig. 1a). To increase Treg 
numbers, we injected mice with IL-2 coupled to the monoclonal antibody JES6-1 (Suppl. Fig. 1d,e). Although this 
particular IL-2/mAb complex was reported to preferentially expand Tregs in vivo46, this treatment expanded both 
Foxp3+ and Foxp3− B3K506 T cells in B3K506 TCR Tg Rag− /− Foxp3 Tg mice (see Supplementary Fig. S1). 
Unlike polyclonal, thymus derived Tregs from B6 mice, B3K506 (monoclonal) Tregs expressed neither Helios nor 
NRP-1. Thymic Tregs in polyclonal mice are thought to be generated through agonist selection5,6 and may acquire 
Helios and NRP-1 expression following a high affinity encounter with self-antigen47. In contrast, thymocytes 
bearing the B3K506 TCR are normally positively selected in the B6 genetic background but are directed into the 
Treg lineage due to expression of the Foxp3 transgene. As B3K506 monoclonal Tregs do not encounter a high 
affinity self-antigen during their development, they are likely Helios− and NRP1− 47,48 (Fig. 1b).
Similar to what was reported for polyclonal Tregs14, we observed decreased IFNγ and IL-2 cytokine levels in 
culture supernatants from suppressive co-cultures containing stimulated B3K506 monoclonal Tregs (Fig. 2b,c). 
Although suppressed OT-II Tconvs produced very little IFNγ (as measured by intracellular staining), suppres-
sion of IL-2 production, as measured by expression of an IL-2-GFP reporter was incomplete (Fig. 2c). In the 
presence of cognate antigen, B3K506 Tregs expanded between 48 and 72h (Fig. 2a). This contradicts previous 
work describing a requirement for Treg anergy to achieve effective suppression13. Using a previously described 
skin-graft-transplantation model45 we observed that B3K506 monoclonal Tregs are less suppressive than poly-
clonal Tregs (50% vs. 100% graft survival, respectively) (Fig. 2d–g). This might be explained by a short half-life of 
3K peptide in vivo, leading to suboptimal Treg activation in the host. However, recipient mice that had accepted 
their skin graft achieved a stable (75d) tolerance and did not require peptide administration past day 15.
To investigate the role of TCR signal strength in B3K506 Treg suppression, we used three altered peptide 
ligands (i.e. 3K, P8G, P2A). Although they display an affinity hierarchy for the B3K506 TCR (3K > P8G > P2A) 
all three pMHC antigens are above the affinity threshold for negative selection49 (Fig. 3a–g). All three peptides 
induced suppression when used at their EC50 concentration for CD69 up-regulation (see Supplementary Fig. S2). 
However, low affinity peptides were more suppressive when used at increased concentrations. Increased peptide 
concentration could compensate for decreased affinity to some extent (Fig. 3c). Overall, suppressive capacity 
correlates with pMHC affinity, peptide concentration, TCR signal strength, B3K506 Treg proliferation and CD25 
expression (Fig. 3d–g).
In accordance with published data50, we did not detect a soluble suppressive molecule in culture supernatants 
from antigen stimulated B3K506 Tregs (Fig. 4a). However suppressive cytokines e.g. IL-10, IL-35 and TGFβ or 
tryptophan metabolites, granzyme B and adenosine may be too diluted or unstable to be suppressive in a relatively 
large culture volume (200 μ l). In this experimental system, CTLA-4 mediated trans-endocytosis of CD8621–23  
was not observed (Fig. 4b). This mechanism of suppression likely plays a minor role in our system. Suppressive 
mechanisms involving the induction of APC apoptosis can also be excluded due to the fact that the numbers of 
surviving APCs in suppressive and non-suppressive co-cultures are similar (Fig. 4b).
Finally, although B3K506 Tregs from suppressive co-cultures expressed surface latency-associated peptide of 
TGF-β (LAP) (see Supplementary Fig. S2), conversion of OT-II Tconvs into iTregs was not observed (Fig. 4c). 
This mechanism of suppression is not evident in our experimental system.
Previously reported experiments using transwell culture settings failed to observe suppression13,14. The authors 
concluded that Treg-to-Tconv-cell-contact has a predominant role in mediating suppression. Along this line, we 
designed an experiment where I-Ab restricted B3K506 Tregs and I-Ed restricted HA Tconvs were co-cultured 
with B6xBALB/c F1 APCs presenting both Treg and Tconv peptides or with separate B6 and BALB/c APCs, 
each presenting the Treg or the Tconv peptides, respectively (Fig. 4d). In this system, neither peptide cross pres-
entation nor cross-reactivity of each T cell on the inappropriate APC was evident (see Supplementary Fig. S2). 
Suppression is enhanced when Tregs and Tconvs received antigen stimulation from F1 APCs presenting both 
peptides. However, partial suppression was detected when cells were cultured on separate APCs. Using separate 
APCs for each antigen, HA Tconvs were able to proliferate to some degree but did not upregulate CD25 (Fig. 4e).
There is likely a combination of more than one suppressive mechanism, which could explain these results. 
Suppression may be mediated by a combination of processes, some of which function more efficiently at short 
distances (e.g. IL-2 scavenging or contact mediated suppression); other mechanisms such as the secretion of 
suppressive molecules might function over longer distances, i.e. even when the proximity between Tregs and 
Tconvs is reduced. Nevertheless the data (Fig. 4d) favor the idea that suppression is more efficient when the Treg 
and Tconv have an increased chance to interact on the same APC, i.e. an APC presenting both the Tconv and the 
Treg antigens.
In summary, we observed that suppression requires high Treg numbers expressing high amounts of surface 
CD25 (Fig. 3) and is enhanced by close proximity between Tregs and Tconvs (Fig. 4d,e). These results, along with 
the observation that addition of exogenous IL-2 abrogates suppression in vitro13,14 (see Supplementary Fig. S2), 
are consistent with the ability of Tregs to scavenge IL-2 which might account for their capacity to suppress Tconvs. 
Supporting this idea are the observations that Tregs continuously, and even more so upon TCR and IL-2 signal-
ling, express CD25 (Fig. 3b and see Supplementary Fig. S2). Moreover, due to the direct repression of the IL-2 
promoter by Foxp3, Tregs are unable to produce autocrine IL-251. A potential, reliable source of paracrine IL-2 
could be a neighbouring CD4+ Tconv cell encountering low affinity self-antigen present in the periphery. The 
uptake of excess paracrine IL-2 by Tregs has beneficial effects on the maintenance of lymphocyte homeostasis: (i) 
by consuming IL-2, the Treg receives a survival signal and maintains elevated CD25 expression (Suppl. Fig. 2C), 
and (ii) by decreasing the amount of IL-2 available to Tconvs, Tregs limit the ability of Tconvs to respond to 
self-antigen.
However, there are a few reports in the literature arguing against IL-2 scavenging as a major mechanism of 
suppression. Tregs from CD25−/− mice are suppressive in vitro39 and mice with a specific deletion of CD122 in 
peripheral Tregs do not suffer from autoimmune disorders40. However these arguments have been mitigated 
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by more recent work showing that CD122 deficient Tregs still respond, albeit to a diminished extent, to IL-2 
signalling41 and Tregs from CD25−/− mice failed to prevent spontaneous encephalomyelitis in vivo52.
Proximity imposed by Treg and Tconv peptide recognition on the same (F1) APC, renders suppression more 
complete (Fig. 4d). This mechanism may be partially active in cultures using two separate APCs due to the high 
density of Tregs. However, in vivo it seems less likely that Tregs and Tconvs responding to antigen on sepa-
rate APCs will achieve sufficient proximity to induce suppression. In the lymph node there is a large excess of 
bystander CD4 and CD8 T cells, which decrease the proximity of Tregs and self-reactive Tconvs. In this light, one 
way to achieve Treg-Tconv proximity in vivo is for the Treg and Tconv to be stimulated by the same APC. Recent 
data using a two-photon microscopy for LN-live imaging showed that Tregs migrate at high velocity and engage 
both Tconv and DC in brief but frequent contacts. The authors conclude that, under non-inflammatory condi-
tions, a LN-resident DC is in contact with at least one Treg for 36–47% of the time53.
Even though IL-2 scavenging is an attractive mechanism for suppression, our study does not exclude a role 
for suppressive mechanisms requiring cell-to-cell contact. It is well possible that Tregs, physically interact with 
Tconvs and mediate suppression, for example, through gap-junction formation, shunting high levels of inhibitory 
cyclic adenosine monophosphate (cAMP) from Tregs to Tconvs36. In addition, a requirement for Treg-Tconv 
proximity is also compatible with the Treg secreting suppressive mediators, which are more effective (i.e. at suf-
ficiently high concentrations) at short distance from the Treg. Finally its worth pointing out that Treg-Tconv 
proximity is not an absolute requirement for suppression, since Tregs display some activity under conditions of 
reduced proximity (Fig. 4d,e).
Additional work is required to fully characterize the multiple mechanisms of Treg-mediated suppression, but 
monoclonal Tregs may be a useful experimental tool for future studies.
Material and Methods
Mice. Foxp3 Tg mice on a C57BL/6 background were described previously43 and kindly provided by S. F. 
Ziegler (Seattle, USA). B3K506 TCR Tg Rag−/− mice on a C57BL/6 background44 were kindly provided by 
P. Marrack and J. Kappler (Denver, USA). B3K506 TCR Tg Foxp3 Tg mice were generated in our lab by crossing 
B3K506 TCR Tg Rag−/− to Foxp3 Tg animals. Foxp3EGFP reporter mice on a C57BL/6 background54 were kindly 
provided by B. Malissen. ABM (anti-bm12) TCR Tg mice on a C57BL/6 background were described previously55. 
IL-2EGFP Reporter mice on a C57BL/6 background56 were kindly provided by A. Freitas (Paris, France). OT-II 
TCR Tg Rag−/− IL-2EGFP reporter mice were generated in our lab by crossing OT-II TCR Tg Rag−/− to IL-2EGFP 
reporter animals. C57BL/6 OT-II TCR Tg mice, C57BL/6 Ly5.1, C57BL/6 Ly5.2, B6.H2-I-Abm12 (bm12) and 
BALB/c mice were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA). C57BL/6.CD3ε -deficient 
mice and BALB/c Ly5.1 HA TCR Tg mice57 were kindly provided by A. Rolink (Basel, Switzerland). All adult mice 
were 6–12 weeks old and bred in our colony (University Hospital Basel); all animal experiments were carried out 
using procedures approved by the Cantonal Veterinary Office in Baselstadt and in accordance with the Cantonal 
and Federal laws of Switzerland. The Cantonal Veterinary Office of Basel-Stadt, Switzerland, approved the animal 
protocols.
Media, Antibodies and reagents. All cells were grown in RPMI 1640 (Gibco /Lifetechnologies) supple-
mented with 10% heat-inactivated FCS. Biotin-conjugated anti-CD3 (145-2C11), Biotin-conjugated anti-CD4 
(RM4-5), Biotin-conjugated anti-CD8 (53-6.7), PE-conjugated anti-CD45.2 (104), Alexa700-conjugated 
anti-IFNγ (XMG1.2), PerCP-conjugated anti-CD45.1 (A20), FITC-conjugated anti-CD69 (H1.2F3), 
FITC-conjugated anti-CD44 (IM7), APC-conjugated anti-CD19 (1D3), PE-conjugated anti-CD62L (Mel-14), 
PE-conjugated anti-CD5 (53-7.3), PerCP-conjugated anti-CD3 (145-2C11), Alexa700-conjugated anti-CD4 
(RM4-5), APC-conjugated anti-CD11a (M17/4), PE-conjugated anti-TCRValpha 2 (B20.1), PE-conjugated 
anti-TCRVbeta 5 (MR9-4) and APC-conjugated anti-TCRVbeta 8 (MR5-2) were purchased from BD 
Pharmigen (www.bdbioscience.com). PerCP-conjugated anti-NRP-1 was purchased from R&D Systems 
Inc. (www.RnDSystems.com). PE-Cy7-conjugated anti-GITR (DTA-1), PE-conjugated anti-TBET (4B10), 
PE-Cy7-conjugated anti-Foxp3 (FJK-16a) and APC-conjugated anti-Helios (22F6) was purchased from eBio-
science (www.eBioscience.com). Pacific blue-conjugated anti-CD4 (RM4-4), Alexa700-conjugated anti-CD86 
(GL-1), APC-conjugated anti-LAP (TW7-16B4), Alexa700-conjugated anti-CD25 (PC61) and APC-conjugated 
anti-CTLA-4 (UC10-4B9) were purchased from BioLegend (San Diego, CA, USA). EasySep Mouse CD4 + T cell 
Isolation Kit and EasySep Mouse B cell Isolation Kit, were purchased from Stemcell Technologies (www.stem-
cell.com). Recombinant Mouse IL-2 was purchased from BioLegend (San Diego, CA, USA). Cell Proliferation 
dye eFluor 670 was purchased from eBioscience (www.eBioscience.com). BD Cytofix/Cytoperm Plus Fixation/
Permeabilization Kit with GolgiStop and BD Cytometric Bead Array Mouse Th1/Th2/Th17 CBA Kit was pur-
chased from BD Pharmigen (www.bdbioscience.com). Anti–IL-2 (JES6-1) and anti-CD3 (145-2C11) were pro-
duced in our lab. Protein G Sepharose 4 Fast Flow, was purchased from (www.gelifescience.com). Peptides 3K 
(FEA QKA KAN KAV), P8G (FEA QKA KAN GAV), P2A (FEA AKA KAN KAV), and OVA (323-339) (ISQ 
AVH AAH AEI NEA GR), were purchased from AnaSpec (Fremont, CA, USA). HA-Peptide (YPY DVP DYA) 
was kindly provided by L. Klein (LMU, Germany). Dynabeads Biotin Binder, Cell trace CFSE and LIVE/DEAD 
fixable Near-IR were purchased from Invitrogen (Eugene, Oregon, USA). PMA and Ionomycin were purchased 
from Sigma-Aldrich.
IL-2 complex treatment. B3K506 Treg mice were injected i.p. with 7.5 μ g anti-IL-2 antibody (JES6-1) cou-
pled to 2.5 μ g mouse rIL-2 in 200 μ l PBS on three subsequent days (see Supplementary Fig. S1). Complex forma-
tion was achieved by incubating IL-2 and JES6-1 in PBS for 30 min at 37 °C.
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Preparation and sorting of lymphocytes. LNs (axillary, inguinal, superficial cervical, mandibular, and 
mesenteric) were harvested from 6–12 week old mice. For single cell preparation, they were passed through a 
mesh into RPMI/10% FCS. B3K506 TCR Tg Foxp3 Tg cell suspensions were then incubated with Pacific Blue con-
jugated anti-CD4 and PE-Cy7 conjugated anti-GITR antibodies for 10 min at 4 °C, washed, and then sorted for 
CD4+ GITR+ cells on a BD INFLUX Cell Sorter (purity ≥ 96%, see Supplementary Fig. S1) into RPMI/10%FCS. 
B6 Foxp3 EGFP cell suspensions were sorted for GFP+ cells on a BD INFLUX Cell Sorter (purity ≥ 98%) into 
RPMI/10%FCS. Spleens were harvested from 6–12 week old mice. For single cell preparation they were passed 
through a mesh into erythrocyte lysis buffer and incubated for 1 min and subsequently washed in RPMI/10% 
FCS. T cell depletion was then preformed with the EasySep Mouse B cell Isolation Kit from Stemcell technol-
ogies (according to manufacture’s protocol) or with Dynabeads Biotin Binder Kit (according to manufacture’s 
protocol, Invitrogen) after incubating the splenocyte suspension for 10 min with biotin-conjugated anti-CD4, 
biotin-conjugated anti-CD8, biotin-conjugated anti-CD3 antibodies.
In vitro suppression culture. 10e5 monoclonal B3K506 Tregs, 10e5 polyclonal B6 FoxP3-EGFP Tregs or 
10e5 monoclonal B3K506 Tconvs (control) were cultured in 96-well plates (0.2 ml) along with 2.5 × 10e4 OT-II 
Tconvs, 10e5 T cell–depleted splenocytes as a source of APCs and 0.1 μ g/ml anti-CD3 or 3K, P8G or P2A peptides 
(at various concentrations, see figures). To experiment in Suppl. Fig. 2f, 50 ng/ml of recombinant Il-2 was added. 
T cell depleted splenocytes were preloaded with 10e-7M OVA (323-339) peptide for 4.5 h at 37 °C and washed 
3x. OT-II Tconv were labeled with 5 μ M CFSE or 5 μ M eFlour 670 according to manufacture’s protocols. Flow 
cytometric analysis of suppressive cultures was preformed after 24, 48 and 72 h.
Staining and Flow cytometry. Surface staining was preformed in PBS/3% FCS at 4 °C for 10 min with 
various antibodies. For intracellular staining, cells were fixed and permeabilized (according to manufacture’s 
protocol) using the Cytofix/Cytoperm Plus Fixation/Permeabilization Kit from BD. Intracellular Foxp3 staining 
was preformed at 4 °C for 1 h. For intracellular cytokine staining cultured cells were re-stimulated with 100 ng/ml 
PMA, 1.5 μ M Ionomycin and 1.5 μ l/ml Monensin (BD Pharmigen) and incubated for 5 h at 37 °C. Flow cytometry 
was preformed with a FACSCanto II from BD Pharmigen (www.bdbioscience.com).
In vivo graft transplantation. Tail skin from B6.bm12 Rag−/− mice was isolated and transplanted onto the 
back of B6 Rag−/− mice and allowed to heal in for 14 days. The following day mice were injected with 2 × 10e4 
ABM (I-Abm12 specific TCR Tg) Tconvs along with 2 × 10e5 Foxp3EGFP polyclonal Tregs or 2 × 10e5 B3 mono-
clonal B3K506 Tregs. One group of mice received 30 μ g 3K peptide/200 μ l PBS injected i.p. every second day until 
day 15 and a second group received no peptide. A control group was injected with 2 × 10e4 ABM Tconvs alone. 
Graft rejection was checked every 2nd day.
Cytokine assay. Culture supernatants were stored at − 80 °C and thawed. The BD Cytometric bead array 
(CBA) system using antibody-coated capture beads was used to quantitate various cytokines in the culture super-
natants (see manufacture’s protocol). Analysis was preformed with Excel software (version 14.4.3) calculating 
unknown sample concentrations from a standard curve.
Determination of CD69 up regulation on B3K506 Tconv cells using various peptides. 10e5 T 
cell depleted splenic B cells (as a source of APCs) were isolated and loaded with varying amounts of peptide for 
4.5 h at 37 °C before addition of 2.5 × 10e4 B3K506 Tconvs. Cells were cultured in 96-well plates (0.2 ml) with 
RPMI/10% FCS for 24 h at 37 °C. T cells were then surface stained (described above) for CD3, CD4 and CD69 and 
flow cytometry was preformed. EC50 values for CD69 upregulation were calculated using a nonlinear regression 
curve (log [agonist] vs. response; three parameters) using Prism, version 6.0b.
Suppression experiments using same or separate APCs. For “same APC” cultures, 10e5 B3K506 
Tregs (I-Ab restricted), 2.5 × 10e4 HA Tg Tconvs (I-Ed restricted) and 10e5 splenic B cells from BALB/c x B6 
F1 mice (co-expressing I-Ed and I-Ab) were cultured in a 96-well plate in 0.2 ml RPMI/10%FCS at 37 °C. For 
“separate APC” cultures, 10e5 B3K506 Tregs (I-Ab restricted), 2.5 × 10e4 HA Tg Tconvs (I-Ed restricted), 10e5 B6 
splenic B cells (I-Ab) and 10e5 BALB/c splenic B cells (I-Ed) were cultured in 96-well plates in RPMI/10%FCS at 
37 °C. 3K peptide (10e-7M) and HA peptide (10e-5M) was added to same and separate APC cultures. Cultures 
were analysed using flow cytometry after 72 h.
Statistics. Cell proliferation Index (PI) was calculated using FlowJo software (version 9.7.7). % Suppression 
was calculated using the formula (100-(% proliferated Tconv from suppressed culture/% proliferated Tconv)*100). 
Curve fitting and statistical analysis was performed using Prism version 6.0b and Excel version 14.4.3.
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